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Background: Parkinson's disease (PD) is one of the most common diseases of the central
nervous system (CNS). It is frequently heralded by speech disturbances, which are one of its
ﬁrst symptoms.
Aim: The aim of this paper is to share our own experience concerning the correlation
between the severity of speech disorders and the PD duration, its severity and the intake of
L-dopa.
Material and methods: The research included 93 patients with idiopathic PD, aged 26–86 years
(mean age 65.1 years). Participants were examined neurologically according to the Uniﬁed
Parkinson's Disease Rating Scale (UPDRS) and the Hoehn and Yahr Scale. They were also
assessed by Frenchay Dysarthria Assessment.
Results: Considerable and severe disorders were concurrent with impairments in the mo-
bility of the tongue, lips, the jaw as well as the pitch and loudness of the voice. The strongest
correlation but at a moderate level was found to exist between the severity of labial
impairment, voice loudness and the length of the disease. There was also a positive
correlation between lip movement while the motions were being diversiﬁed, lip arrange-
ment while speaking and the intake of L-dopa.
Conclusions: As PD progresses a signiﬁcant decline in vocal articulation can be observed,
which is due to reduced mobility within the lips and the jaw. Exacerbation of articulation
disorders resulting from progression of the disease does not materially inﬂuence the
UPDRSS scores. L-dopa has been found to positively affect the mobility of the lips while
the patient is speaking and their arrangement at rest.
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of the central nervous system (CNS). It is frequently heralded
by speech disturbances, which are one of its ﬁrst symptoms
[1,2] present in up to 89% of parkinsonian patients [3]. Most of
them do not perceive their communication problems [1,4].
Impaired speech results from the patients' articulation,
phonation and breathing dysfunction, which consequently
leads to reduced loudness, lack of rhythm and pace of speech,
numerous pauses, reduction of stress as well as improper
consonant articulation [5,6].
Studies show imprecise articulation of consonants /p/, /b/,
/s/, /f/, as well as /R/ and /a/ [7,8].
The quality of articulation is inﬂuenced by the pace of
speech, which, apart from the disease itself, is also affected by
patients' age. There are few studies into the relation between
the exacerbation of the movement disorder within the speech
organs and duration of the disease, its severity and L-dopa
dosage. The ﬁndings are inconsistent. Some of those studies
show that relation does exist [9–14]. On the other hand,
research carried out with the application of the measurement
of energy concentration in an acoustic spectrum of an acoustic
image of vowels of the lower formants F1 and F2 shows lack of
connection between duration of the diseases, its severity and
motor symptoms [15]. It needs to be noted though that the
subjects were patients with mild speech impairment. Al-
though various studies attempted to show the relation
between the dosage of L-dopa and the quality of speech in
PD patients, the results are still inconclusive [16–19].
Diverse research into speech disorders in PD patients has
been conducted and although many techniques of acoustic
analysis [18], videoscopic examination [20] and positron
emission tomography [21,22] have been applied, the mecha-
nism responsible for the onset of speech disorders in PD has
not been identiﬁed yet.
The aim of this paper is to share our experience concerning
the correlation between the severity of speech disorders and
the PD duration, its severity and the intake of L-dopa.
Material and method
The study involved 93 patients diagnosed with PD, 33 (35.5%
women; aged between 26 and 86 – average 65.1 years. PD was
diagnosed by means of neurological examinations, biochemi-
cal tests and MRI and CT scanning in accordance with the
United Kingdom Parkinson's Disease Society Brain Bank
(UKPDSBB) criteria [23]. Duration of the illness, measured
from the occurrence of the ﬁrst symptoms of PD, varied from 1
month to 27 years (average 7.5 years). Daily intake of L-dopa
ranged from 150 to 2000 mg, on average 570.9 mg.
The Uniﬁed Parkinson's Disease Rating Scale (UPDRS) [23]
and the 5-stage Hoehn and Yahr Scale [24] were used for the
assessment of the severity of the disease.
A speech and language test involved the assessment of
the mobility of the speech organs as well as the reﬂexes
inside the oral cavity. Frenchay Dysarthria Assessment – FDA
[25], an objective test for the assessment of the vocal organs
and the severity of speech disorders, was applied. The test
enables monitoring both the effect of the therapy and the
severity of speech disturbances. A 5-point rating scale (a–e)is used for the assessment, where letter 'a' represents norm,
'b' mild severity, 'c' moderate, 'd' considerable severity, 'e'
very high severity. The test evaluates the following func-
tions: swallowing, breathing, performance of the tongue,
lips, the soft palate and the jaw as well as the pitch and
loudness of the voice.
Patients with considerable deviation from the norm were
referred for laryngological consultations so that possible other
conditions within the speech organs could be ruled out.
The study was approved by the Pomeranian Medical
University Commission of Ethics – Resolution no KB-0012/
07/10 of 21 January 2010.
Statistical analysis
The analysis of the results was carried out by means of
STATISTICA – a statistics and analytics software package for
Windows 10. Distributions of the answers to the survey
questions were analyzed through the application of tables of
descriptive statistics and multiplicity charts. In case of
variables measured on quantitative scales, the Shapiro–Wilk
test [26] was used to determine whether the obtained
distributions were in conformity with hypothetically standard
normal distribution or signiﬁcantly different. The Mann–
Whitney U [27] test was applied in order to analyze the
differences between the quantitative scales distributions and
grouping qualitative variables. The statistical dependence
between the variables on the quantitative scales was analyzed
by means of an estimated Spearman's rank correlation
coefﬁcient. Level p < 0.05 was adopted as signiﬁcant and
p < 0.01 highly signiﬁcant [28,29].
Results
Table 1 shows the relationship between articulation disorders
and their severity on the FDA scale. Considerable and severe
disorders were concurrent with impairments in the mobility of
the tongue, lips, the jaw as well as the pitch and loudness of
the voice.
Table 2 illustrates the correlation between articulation
disorders evaluated by means of the objective FDA test and the
duration of the disease. The strongest correlation at a
moderate level was found to exist between the severity of
labial impairment, voice loudness and the length of the
disease. There was also a positive correlation between
arrangement of the lips, jaw movement during speaking,
the pitch and the duration of the disease. No correlation was
found between articulation disorders and severity of PD
measured on UPDRS scale. A hardly material tendency was
found in the relation between the arrangement of the lips
during speaking and the severity of the disease (R Spearman
0.2881, p = 0.0610). No correlation was found between articu-
lation disorders and a stage of the disease measured according
to the Hoehn and Yahr scale.
According to Table 3 there was a positive correlation
between lip movement while the motions were being
diversiﬁed, lip arrangement while speaking and the intake
of L-dopa.
Table 1 – Articulation disorders and the degree of their
intensity according to the FDA scale.
Speech organ Intensity No. of patients %
Cough reﬂex Mild 11 11.83
Moderate 2 2.15
Considerable 1 1.07
Swallowing reﬂex Mild 27 29.03
Moderate 3 3.23
Dribble/drool reﬂex Mild 58 62.37
Moderate 4 4.30
Respiration Mild 36 38.70
Moderate 7 7.53
Considerable 1 1.07
Lips Mild 47 50.4
Moderate 11 11.8
Considerable 3 3.2
Jaw Mild 38 40.8
Moderate 7 7.53
Considerable 1 1.07
Soft palate Mild 37 39.78
Moderate 3 3.22
Laryngeal time Mild 28 30.11
Moderate 38 40.86
Considerable 9 9.68
Laryngeal pitch Mild 57 61.29
Moderate 17 18.28
Considerable 3 3.23
Laryngeal volume Mild 56 60.21
Moderate 15 16.13
Considerable 3 3.23
Tongue Mild 46 49.46
Moderate 35 37.63
Considerable 36 38.70
Severe 3 3.22
Table 2 – Correlations between articulation disorders
assessed by means of the FDA test and the duration of PD.
Number
of patients
Spearman's
rho
Level p
Lips at rest 92 0.3113 0.0025b
Lips – movement
diversiﬁcation
92 0.3212 0.0018a
Lips movement
while speaking
92 0.2295 0.0278b
Mandible movement
while speaking
92 0.2187 0.0362b
Pitch 92 0.2066 0.0482b
Loudness 92 0.2711 0.0089a
a p < 0.01 – highly statistically significant relationship.
b p < 0.05 – statistically significant relationship.
Table 3 – Correlations between articulation disorders
assessed by means of the FDA test and the daily intake of
L-dopa.
Number of
patients
Spearman's
rho
Level p
Lips – movement
diversiﬁcation
Level p 0.3681 0.0152b
Lips movement
while speaking
Level p 0.3834 0.0112b
a p < 0.01 – highly statistically signiﬁcant relationship.
b p < 0.05 – statistically signiﬁcant relationship.
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Articulation disorders in PD have not been widely described in
relevant literature. The items most frequently studied includ-
ed: the length of a consonant sound [30], pace of vowelsuttered [31] and the performance of particular speech organs –
the tongue, the lips, the jaw and the soft palate [1,4]. I have
found that the quality of speech in PD is affected by reduced
mobility of speech organs and a slower pace of performed
movements. Dysfunctions most frequently occur within the
tongue, lips and jaw [6].
Our study also shows a reduced range of motion of the
tongue, lips, jaw and the soft palate. We also looked into a
possible correlation between articulation disorders in PD,
stage of the disease and dosage of L-dopa. An increased
severity of speech disorders in patients with a long duration of
the disease is also observed. Canter [31] ascertained that PD of
long duration leads to the stiffness of the jaw and lips, which
consequently leads to slurred speech and poor articulation of
labial phones. Raming et al. [32] observed an increased extent
of vocal disorders in people with a long duration of the disease.
Caviness et al. [33] did not ﬁnd any correlation between the
duration of PD and the severity of articulation disorders in PD
patients.
Observing our test group PD patients we found a relation
between distorted lip performance during their movement,
their arrangement at rest, improper jaw movement resulting
from its stiffness and the duration of the disease. No
dependency between the duration of the disease and
disturbances in breathing and phonation was found. It can
be ascertained though that the progression of the disease
materially affected the quality of speech in PD patients.
Research on the inﬂuence of the progression of PD on
speech disorders has not yet provided conclusive evidence
[34,35]. Some authors believe that the progression of the
disease particularly affects the performance of speech organs
and mimic muscles. Amimia, a loss of the power to give facial
expression to emotion, occurs. Skodda et al. [36] reported a
decline in lip performance during articulation and a patholog-
ical position of the lips at rest in 50 PD patients. Impaired
tongue mobility during articulation was also observed. The lips
were not completely closed or remained continuously 6 mm
open. The latest studies carried out by the team [36], however,
do not show positive correlation between the progression of
PD and the length of articulation. Research into the inﬂuence
of the progression of PD on breathing and phonation functions
is scarce. Only Holmes et al. [37] established that the severity of
phonation impairment in the form of laryngeal tremor in PD
patients increased with the development of the disease. That
dependency was not conﬁrmed by Skodda et al. [36].
Having studied our PD patients we found no connection
between impaired breathing, phonation, articulation and a
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disorders within the performance of the speech organs are too
subtle, and in the context of comprehensive evaluation of the
PD patients by means of the UPDRS scale the scope of those
disorder is difﬁcult to assess.
So far, studies investigating the inﬂuence of L-dopa on the
quality of speech have produced various results [16–19]. There
are few publications where the positive effect of L-dopa
treatment on speech disorders could be objectively conﬁrmed.
Its positive effect on the improvement of speech was found in
the ﬁrst 2–5 years of the drug treatment, which was then
followed by the progression of speech quality in the subse-
quent years [9]. In another work it was shown that PD patients
treated with L-dopa showed less severe dysarthric symptoms,
but those ﬁndings were based on subjective auditory evalua-
tion [10]. It was also observed that L-dopa can bring about
improvements in articulation and variability of pitch, mobility
of the lips especially while the patient was speaking,
articulation of labial consonants, performance of the lips,
prosody and the pace of speech [12–14]. It does not materially
improve phonation features or cause the improvement of the
speed of speech in PD patients [16,22]. Latest research done
before the start of L-dopa therapy and after the drug has been
taken in for 6 years shows that a long-term therapy even
contributes to the exacerbation of pauses in speech, which in
turn results in a poorer quality of speech [38].
The data we gathered showed a relationship between
L-dopa doses and the ﬁtness of the lips during the variation of
their movement and position while speaking. The improve-
ment in the movement of the lips, though, was insigniﬁcant.
Even though some of our patients showed a slightly better
articulation after L-dopa treatment, the quality of speech
remained basically unaffected. There was no improvement in
articulation, nor did L-dopa treatment improve phonation or
breathing.
Conclusions
1. As PD progresses a signiﬁcant decline in vocal articulation
can be observed, which is due to reduced mobility within
the lips and the jaw.
2. Exacerbation of articulation disorders connected with the
duration of the disease does not materially inﬂuence the
UPDRSS scores.
3. Of the many functions of the articulating organs, L-dopa
positively affects the mobility of the lips while the patient is
speaking and their arrangement at rest.
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